Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction

Phase 4 Terminated 12 enrolled University of Kansas Medical Center

RandomizedParallel-groupSingle-blindTreatment

Summary

This study intends to determine if any correlation exists between administration of TXA or not to musculoskeletal oncology patients undergoing endoprosthetic reconstruction and blood loss and blood transfusion rates.

Timeline

Start: 2020-01-28
Primary completion: 2023-08-18
Completion: 2023-08-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Tranexamic Acid	Small molecule	1 g	Intravenous

Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction

Summary

Timeline

Drugs

Indications